PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.95%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.25%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
3.35%
Gross profit growth of 3.35% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-4.69%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-15.56%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
4.01%
Net income growth of 4.01% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
4.00%
EPS growth of 4.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
4.00%
Diluted EPS growth of 4.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.04%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.01%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.70%
10Y revenue/share CAGR below 50% of Medical - Pharmaceuticals median of 14.10%. Jim Chanos would suspect deep structural or market share issues.
2.70%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect structural disadvantages or a higher share base limiting per-share growth.
-21.41%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 4.55%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 2.14%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-100.00%
Negative 3Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
7.58%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
7.58%
5Y net income/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff would encourage better profitability or share buybacks to catch up with peers.
-26.90%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
36.05%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 9.97% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
36.05%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 23.46%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-8.39%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 17.20%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.29%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
25112.50%
AR growth of 25112.50% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
1.54%
Inventory growth of 1.54% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
10.94%
Asset growth of 10.94% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.72%
BV/share growth of 4.72% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
116.68%
Debt growth of 116.68% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.